These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 10193429)
21. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Webster S; Glabe C; Rogers J Biochem Biophys Res Commun; 1995 Dec; 217(3):869-75. PubMed ID: 8554610 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. Sárvári M; Vágó I; Wéber CS; Nagy J; Gál P; Mák M; Kósa JP; Závodszky P; Pázmány T J Neuroimmunol; 2003 Apr; 137(1-2):12-8. PubMed ID: 12667643 [TBL] [Abstract][Full Text] [Related]
23. Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation. Li M; Ager RR; Fraser DA; Tjokro NO; Tenner AJ Mol Immunol; 2008 Jun; 45(11):3244-52. PubMed ID: 18400300 [TBL] [Abstract][Full Text] [Related]
25. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Veerhuis R; Van Breemen MJ; Hoozemans JM; Morbin M; Ouladhadj J; Tagliavini F; Eikelenboom P Acta Neuropathol; 2003 Feb; 105(2):135-44. PubMed ID: 12536224 [TBL] [Abstract][Full Text] [Related]
26. Localization and cell association of C1q in Alzheimer's disease brain. Afagh A; Cummings BJ; Cribbs DH; Cotman CW; Tenner AJ Exp Neurol; 1996 Mar; 138(1):22-32. PubMed ID: 8593893 [TBL] [Abstract][Full Text] [Related]
27. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. Webster S; Bradt B; Rogers J; Cooper N J Neurochem; 1997 Jul; 69(1):388-98. PubMed ID: 9202333 [TBL] [Abstract][Full Text] [Related]
28. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. Wahrmann M; Exner M; Regele H; Derfler K; Körmöczi GF; Lhotta K; Zlabinger GJ; Böhmig GA J Immunol Methods; 2003 Apr; 275(1-2):149-60. PubMed ID: 12667679 [TBL] [Abstract][Full Text] [Related]
29. Studies on the mechanisms of allergen-induced activation of the classical and lectin pathways of complement. Varga L; Szilágyi K; Lõrincz Z; Berrens L; Thiel S; Závodszky P; Daha MR; Thielens NM; Arlaud GJ; Nagy K; Späth P; Füst G Mol Immunol; 2003 May; 39(14):839-46. PubMed ID: 12686499 [TBL] [Abstract][Full Text] [Related]
30. C1q-calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease. Luo X; Weber GA; Zheng J; Gendelman HE; Ikezu T J Neuroimmunol; 2003 Feb; 135(1-2):62-71. PubMed ID: 12576225 [TBL] [Abstract][Full Text] [Related]
31. Specific inhibition of the classical complement pathway by C1q-binding peptides. Roos A; Nauta AJ; Broers D; Faber-Krol MC; Trouw LA; Drijfhout JW; Daha MR J Immunol; 2001 Dec; 167(12):7052-9. PubMed ID: 11739526 [TBL] [Abstract][Full Text] [Related]
32. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. Fonseca MI; Zhou J; Botto M; Tenner AJ J Neurosci; 2004 Jul; 24(29):6457-65. PubMed ID: 15269255 [TBL] [Abstract][Full Text] [Related]
33. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. Lu JH; Thiel S; Wiedemann H; Timpl R; Reid KB J Immunol; 1990 Mar; 144(6):2287-94. PubMed ID: 2313094 [TBL] [Abstract][Full Text] [Related]
34. Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Brachova L; Lue LF; Schultz J; el Rashidy T; Rogers J Brain Res Mol Brain Res; 1993 Jun; 18(4):329-34. PubMed ID: 8326828 [TBL] [Abstract][Full Text] [Related]
35. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes. Wouters D; Brouwer MC; Daha MR; Hack CE Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386 [TBL] [Abstract][Full Text] [Related]
36. Classical pathway deficiencies - A short analytical review. Truedsson L Mol Immunol; 2015 Nov; 68(1):14-9. PubMed ID: 26038300 [TBL] [Abstract][Full Text] [Related]
37. Synthesis of classical pathway complement components by chondrocytes. Bradley K; North J; Saunders D; Schwaeble W; Jeziorska M; Woolley DE; Whaley K Immunology; 1996 Aug; 88(4):648-56. PubMed ID: 8881771 [TBL] [Abstract][Full Text] [Related]
38. Activation of the classical complement pathway in brain tissue of Alzheimer patients. McGeer PL; Akiyama H; Itagaki S; McGeer EG Neurosci Lett; 1989 Dec; 107(1-3):341-6. PubMed ID: 2559373 [TBL] [Abstract][Full Text] [Related]
39. Antibody-independent classical complement pathway activation and homologous C3 deposition in xeroderma pigmentosum cell lines. Kurita M; Matsumoto M; Tsuji S; Kawakami M; Suzuki Y; Hayashi H; Toyoshima K; Seya T Clin Exp Immunol; 1999 Jun; 116(3):547-53. PubMed ID: 10361249 [TBL] [Abstract][Full Text] [Related]
40. Complement activation by C-reactive protein on the HEp-2 cell substrate. Vaith P; Prasauskas V; Potempa LA; Peter HH Int Arch Allergy Immunol; 1996 Oct; 111(2):107-17. PubMed ID: 8859218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]